Additional information is available at the following sites:
This listing is provided as a resource only and does not constitute an endorsement by Grifols of any particular organization or its programming. Grifols does not review or control the content of non-Grifols websites.
Frequently Asked Questions (FAQs)
The Rh factor is an antigen that is found on the surface of red blood cells. If your patients have these antigens on their red blood cells, they would be considered Rh positive. Those who do not are Rh negative.1
When an Rh-negative woman has Rh-positive antibodies in her blood and the baby she is carrying is Rh positive, the antibodies could possibly enter the baby's bloodstream, attack the baby's red blood cells, and cause HDN.1
The exchange of blood usually occurs during delivery but can happen during a miscarriage, amniocentesis, or as a result of an injury or trauma. There have also been instances where women develop antibodies to Rh-positive blood cells during pregnancy for no apparent reason.1
If a baby is born with HDN, the infant may suffer from jaundice, anemia, or have permanent damage to the brain and central nervous system. HDN can lead to mental handicaps, hearing loss, or cerebral palsy.1
Extensive medical assistance may be necessary, including an exchange transfusion, which is where the baby's blood is replaced. By transfusing all of the baby's blood, the destruction of his or her red blood cells should stop, giving the baby a chance to survive.1
Yes, prevention is key to protection. HyperRHO S/D is an immune globulin that, when administered properly, can prevent HDN, assuming that the mother does not already have Rh-positive antibodies in her system. HyperRHO S/D has high levels of specific antibodies against Rh-positive blood cells. When injected, HyperRHO S/D destroys any Rh-positive red blood cells that may have entered the mother's body. The injection also prevents the mother's immune system from further production of Rh-positive antibodies, thereby protecting the baby from contracting HDN.1
Because laboratory findings have shown the development of Rh-positive antibodies during the final weeks of pregnancy, you may suggest a first dose be given at 28 weeks' gestation. HyperRHO S/D Full Dose should be administered again within 72 hours of delivery of an Rh-positive baby. For women undergoing spontaneous or induced abortion of up to 12 weeks' gestation, HyperRHO S/D Mini-Dose should be administered within 3 hours or as soon as possible following the abortion.1,2